TABLE 1

Characteristics of islet cell Ab and Ab+ obese youth clinically diagnosed with type 2 diabetes and obese control subjects

Clinically diagnosed type 2 diabetic patients
Obese control subjectsP value
AbAb+ANOVAPost hoc
n162639
Age (years)14.7 ± 0.4 (10.1–17.2)14.9 ± 0.4 (10.2–18.3)14.1 ± 0.2 (12.3–17.2)NSNS
Sex (male/female)7/911/1523/16NS
Ethnicity (African American/Caucasian)6/1013/1320/19NS
Tanner stages
    II-III2310NS
    IV-V142329
BMI (kg/m2)36.0 ± 1.3 (28.3–45.4)33.4 ± 1.2 (24.5–48.9)36.0 ± 0.9 (28.0–49.6)NSNS
Body fat (%)40.6 ± 1.8 (24.9–48.4)40.8 ± 1.5 (22.6–52.9)42.3 ± 0.8 (32.1–51.1)NSNS
VAT (cm2)79.0 ± 6.9 (47.1–142.8)72.8 ± 8.6 (26.5–242.4)76.1 ± 5.9 (16.7–161.4)NSNS
Subcutaneous adipose tissue (cm2)520.1 ± 40.7 (291.6–776.1)491.5 ± 29.8 (264.9–764.4)556.1 ± 23.9 (321.2–890.1)NSNS
Diabetes duration (months)4.4 ± 1.4 (0.05–18.0)9.0 ± 2.1 (1.0–39.0)NANS
A1C (%)6.8 ± 0.2 (4.7–8.3)6.5 ± 0.2 (5.1–8.0)5.3 ± 0.1 (4.3–6.2)<0.001NS
Treatment modality [n (%)]NA
    Lifestyle modification4 (25)5 (19.2)NS
    Metformin6 (37.5)7 (26.9)NS
    Insulin2 (12.5)4 (15.4)NS
    Insulin and metformin4 (25)10 (38.5)NS
  • Data are means ± SEM (range) or n (%). NA, not applicable. Post hoc P value, Bonferonni correction for Ab vs. Ab+ clinically diagnosed type 2 diabetic patients. χ2 analyses with respect to ethnicity, sex, Tanner stage, and treatment modality.